The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Testosterone / TRT

T · Testosterone Cypionate · Testosterone Enanthate · Testosterone Cypionate · Test E · AndroGel · Natesto · Jatenzo · TRT · Testosterone Replacement Therapy

A
Strong human RCT
FDA-approvedAndrogenAnabolic SteroidHormone Replacement Therapy
RouteInjectableFDA-approved
A
Evidence grade: Strong human RCT

Multiple high-quality randomized controlled trials in humans. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Testosterone Replacement Therapy — Exogenous Androgens — The Foundation Compound — Androgen, Anabolic Steroid, Hormone Replacement Therapy.
Why people use it
Used primarily for hormonal support and muscle and performance.
What the evidence supports
3 months, 6 months, then annually; trough = just before next injection
If you only read one thing

Testosterone deficiency is genuinely associated with increased cardiovascular risk, metabolic syndrome, cognitive decline, reduced bone density, reduced quality of life, and anemia — and TRT in confirmed hypogonadal men addresses all of these outcomes with Grade A evidence (TTrials, NEJM 2016; TRAVERSE, NEJM 2023). At the same time: supraphysiological testosterone in eugonadal men produces dose-dependent adverse effects — erythrocytosis, left ventricular hypertrophy, dyslipidemia (HDL reduction), prostate stimulation, HPTA suppression, testicular atrophy, infertility, and in some contexts cardiovascular harm. The divide between these two clinical contexts is not arbitrary — it is pharmacologically meaningful. Testosterone restoring a deficient man to normal levels is metabolically distinct from testosterone elevating a normal man to supraphysiological levels. This chapter treats these as distinct pharmacological situations requiring distinct evidence-based discussions.

Check interactions →
Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
5human RCTs0human studies0animal0in vitro
Evidence reality check
Human evidence
5 human studies
5 randomized; 0 observational.
Preclinical base
0 lab signals
0 animal; 0 in-vitro/mechanistic.
Evidence snapshot
3 months, 6 months, then annually; trough = just before next injection
From the chapter quick-reference block.
  • What are the long-term (10+ year) cardiovascular effects of TRT? TRAVERSE followed men for a median 33 months. The TTrials Cardiovascular sub-trial's finding of increased non-calcified plaque may have clinical significance over longer timescales that the MACE-powered TRAVERSE study was not designed to detect.
  • Is TRT safe and beneficial in prostate cancer survivors? Emerging data suggests physiological TRT is tolerable in selected men after treatment for localized prostate cancer, but the evidence base is limited and guidelines remain conservative.
  • What is the optimal TRT protocol for fertility preservation — HCG alone, gonadorelin alone, Natesto, or combination? Comparative data between these approaches is limited.
  • Does TRT reduce all-cause mortality in hypogonadal men? Observational data consistently shows lower T associated with higher mortality; whether TRT corrects this mortality signal is not definitively established in a powered RCT.
  • What are the cognitive effects of TRT in younger hypogonadal men (under 65)? TTrials enrolled men ≥65; the cognitive data in younger men is limited.
Categories
Hormonal & HPTAMuscle & PerformanceLibido & Sexual Health
Properties
Active malignancy: hard stopWADA S1✓ FDA-approved✓ Human RCTHPTA: suppressive
Half-life
Testicular size (monitoring for atrophy and HCG use decision)."},{"label":"Formulations Overview","value":"Injectable esters (most common community): Testosterone cypionate (t1/…
Evidence
AStrong human RCT
Hypogonadism Diagnosis
Clinical hypogonadism = confirmed low testosterone + symptoms. Diagnostic criteria (Endocrine Society guidelines): (1) Total testosterone <300 ng/dL on two separate morning blood draws (8-10 AM) at least 48 hours apart; (2) Presence of symptoms: reduced libido, reduced spontaneous erections, reduced energy/fatigue, depressed mood, reduced lean mass/increased fat, hot flushes, osteoporosis, anemia. Both criteria must be met. Total testosterone <300 ng/dL alone without symptoms does not meet clinical criteria for treatment. The normal reference range is approximately 300-1,000 ng/dL; TRT targets mid-normal range (400-700 ng/dL).
The TRAVERSE Trial — Cardiovascular Safety Settled
TRAVERSE (NEJM June 2023; Bhasin S, Lincoff AM et al.): The FDA-required cardiovascular outcomes trial for TRT. n=5,204 hypogonadal men; age 45-80; preexisting or high CV risk; DBRPC; testosterone 1.62% transdermal gel vs placebo. Primary endpoint: MACE (cardiovascular death, nonfatal MI, nonfatal stroke). Result: non-inferiority confirmed — TRT was not associated with increased MACE. This settled 10 years of cardiovascular controversy after two 2013-2014 observational studies raised concerns. TRAVERSE is now the definitive evidence that TRT does not increase MACE in appropriately selected hypogonadal men with CV risk. NOTE: this applies to TRT (physiological testosterone restoration in hypogonadal men) — not supraphysiological dosing in eugonadal men.
Key Monitoring Parameters
BEFORE starting: Total testosterone (x2 morning), LH, FSH, SHBG, free testosterone, prolactin, PSA, CBC (hematocrit), lipid panel, metabolic panel, testicular exam. DURING TRT: Testosterone levels at 3 and 6 months then annually (target 400-700 ng/dL mid-cycle); Hematocrit at 3 and 6 months then annually (hold TRT if >54%); PSA at 3-6 months then annually; Estradiol (E2) if symptoms of excess (water retention, gynecomastia, mood); Lipids annually; Testicular size (monitoring for atrophy and HCG use decision).
Formulations Overview
Injectable esters (most common community): Testosterone cypionate (t1/2 ~8 days; every 7-14 days injection); Testosterone enanthate (t1/2 ~5 days; every 7-10 days); Testosterone propionate (t1/2 ~2 days; every 2-3 days; less used for TRT). Topical: 1% or 1.62% testosterone gel (Androgel, Testim); cream; nasal gel (Natesto). Oral: Testosterone undecanoate (Jatenzo; expensive; hepatic first-pass avoidance required). IM undecanoate (Aveed; 3-month injection). Pellets: implanted subcutaneously; last 3-6 months; popular in specialty clinics.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Enclomiphene
C
Shared goal · hormonal

The Pure Active Isomer in Clomid. The Drug That Raised Testosterone as Well as TRT While Preserving Fertility — and Still Failed FDA Approval. The Zuclomiphene Problem: Why the Racemic Mixture Causes Side Effects Pure Enclomiphene Shouldn't. The NDA That Died in 2021. How It Differs from TRT, HCG, and Gonadorelin for Male Hypogonadism. The 2025 Meta-Analysis: +273 ng/dL Testosterone vs Placebo.

Human Chorionic Gonadotropin
B
Shared goal · hormonal

FDA-Approved for Fertility and Male Hypogonadism. The Most Important Hormone in Post-Cycle Therapy. The Active Ingredient in the Simeons 500-Calorie Diet — a Fraud With Its Own FDA Warning. WADA S2 Banned. A Tumor Marker. Three Completely Different Identities in One Glycoprotein.

L-Carnitine
B
Shared goal · muscle

Amino-acid-derived quaternary ammonium compound involved in mitochondrial fatty-acid transport. Commercial claims are often overstated, but specific forms have clinical evidence for neuropathy, peripheral artery disease, muscle recovery, male infertility, and post-MI cardiac outcomes.

Check interactions